Ratings by Leerink (Andrew Berens)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2026 | Celcuity Inc | CELC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2026 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2026 | Regeneron Pharma | REGN | Downgrade | Market Perform (Outperform) |
698.25 (618.03) |
-11.49% | Details | |
| 5/14/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2026 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2026 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2026 | Sensei Biotherapeutics | SNSE | New Coverage | Outperform (N/A) |
30.49 (13.85) |
-54.58% | Details | |
| 4/13/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2026 | Terns Pharmaceuticals | TERN | Downgrade | Market Perform (Outperform) |
52.62 (52.95) |
0.63% | Details | |
| 4/7/2026 | Sutro Biopharma | STRO | New Coverage | Outperform (N/A) |
23.95 (29.19) |
21.88% | Details | |
| 3/30/2026 | OnKure Therapeutics Inc. | OKUR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2026 | Damora Therapeutics | DMRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Outperform (N/A) |
7.36 (10.60) |
44.02% | Details | |
| 3/10/2026 | Boundless Bio Inc. | BOLD | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/9/2026 | Terns Pharmaceuticals | TERN | New Coverage | Outperform (N/A) |
37.77 (52.62) |
39.32% | Details | |
| 1/30/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Galecto | GLTO | New Coverage | Outperform (N/A) |
21.84 (28.69) |
31.36% | Details | |
| 12/17/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2025 | Celcuity Inc | CELC | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Cullinan Oncology Inc. | CGEM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2025 | Agios Pharma | AGIO | Upgrade | Outperform (Market Perform) |
22.34 (35.59) |
59.31% | Details | |
| 11/19/2025 | Zymeworks | ZYME | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2025 | Zymeworks | ZYME | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2025 | Celcuity Inc | CELC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/10/2025 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2025 | Immuneering Corporation | IMRX | New Coverage | Outperform (N/A) |
6.41 (4.54) |
-29.17% | Details | |
| 10/6/2025 | Merus N.V. | MRUS | Downgrade | Market Perform (Outperform) |
94.15 (90.00) |
-4.41% | Details | |
| 9/17/2025 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (N/A) |
0.00 (7.50) |
0% | Details | |
| 9/9/2025 | Ideaya Biosciences | IDYA | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/4/2025 | Agios Pharma | AGIO | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/11/2025 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2025 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/27/2025 | BeOne Medicines | ONC | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2025 | Nuvalent | nuvl | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Arvinas Inc. | ARVN | Downgrade | Market Perform (Outperform) |
7.50 (8.14) |
8.53% | Details | |
| 4/17/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/2/2025 | Compass Therapeutics | CMPX | Upgrade | Outperform (Market Perform) |
2.24 (2.06) |
-8.04% | Details | |
| 3/21/2025 | Elevation Oncology | ELEV | Downgrade | Market Perform (Outperform) |
0.48 (0.37) |
-22.92% | Details | |
| 2/5/2025 | Regeneron Pharma | REGN | Upgrade | Outperform (Market Perform) |
697.05 (618.03) |
-11.34% | Details | |
| 1/28/2025 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/17/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2024 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2024 | OnKure Therapeutics Inc. | OKUR | New Coverage | Outperform (N/A) |
14.18 (4.20) |
-70.38% | Details | |
| 12/4/2024 | Relay Therapeutics | RLAY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | Zymeworks | ZYME | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2024 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2024 | Compass Therapeutics | CMPX | Downgrade | Market Perform (Outperform) |
1.59 (2.06) |
29.56% | Details | |
| 11/7/2024 | Zymeworks | ZYME | Upgrade | Outperform (Market Perform) |
15.61 (23.88) |
52.98% | Details | |
| 11/5/2024 | Ideaya Biosciences | IDYA | Downgrade | Market Perform (Outperform) |
30.00 (34.91) |
16.37% | Details | |
| 11/1/2024 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/31/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2024 | Gilead Sciences | GILD | Upgrade | Outperform (Market Perform) |
86.72 (125.05) |
44.2% | Details | |
| 10/17/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/15/2024 | Agios Pharma | AGIO | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/15/2024 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/27/2024 | Agios Pharma | AGIO | Downgrade | Market Perform (Outperform) |
48.05 (22.34) |
-53.51% | Details | |
| 9/24/2024 | Regeneron Pharma | REGN | Downgrade | Market Perform (Outperform) |
1091.98 (618.03) |
-43.4% | Details | |
| 8/16/2024 | Viracta Therapeutics | VIRX | Downgrade | Market Perform (Outperform) |
0.38 (0.08) |
-78.95% | Details | |
| 7/22/2024 | Celcuity Inc | CELC | New Coverage | Outperform (N/A) |
17.28 (90.21) |
422.05% | Details | |
| 6/3/2024 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2024 | Blueprint Medicines | BPMC | Upgrade | Market Perform (Underperform) |
107.19 (129.46) |
20.78% | Details | |
| 4/29/2024 | Deciphera | DCPH | Downgrade | Market Perform (Outperform) |
14.65 (25.59) |
74.68% | Details | |
| 4/1/2024 | Nuvalent | NUVL | Upgrade | Outperform (Market Perform) |
75.09 (123.44) |
64.39% | Details | |
| 1/29/2024 | Immunome Inc. | IMNM | New Coverage | Outperform (N/A) |
17.48 (19.33) |
10.58% | Details | |
| 11/7/2023 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Market Perform (Outperform) |
12.48 (3.68) |
-70.51% | Details | |
| 11/7/2023 | Mirati Therapeutics | MRTX | Downgrade | Market Perform (Outperform) |
56.27 (58.70) |
4.32% | Details | |
| 6/26/2023 | BeiGene, Ltd. | BGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2023 | Blueprint Medicines | BPMC | Downgrade | Underperform (Market Perform) |
58.22 (129.46) |
122.36% | Details | |
| 5/30/2023 | Elevation Oncology | ELEV | Upgrade | Outperform (Market Perform) |
5.02 (0.37) |
-92.63% | Details | |
| 3/27/2023 | Regeneron Pharma | REGN | Upgrade | Outperform (Market Perform) |
820.00 (618.03) |
-24.63% | Details | |
| 2/10/2023 | Abbvie | ABBV | Upgrade | Market Perform (Underperform) |
148.70 (234.76) |
57.87% | Details | |
| 12/21/2022 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2022 | Elevation Oncology | ELEV | Downgrade | Market Perform (Outperform) |
0.95 (0.37) |
-61.05% | Details | |
| 11/2/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2022 | Zymeworks | ZYME | Downgrade | Market Perform (Outperform) |
6.45 (23.88) |
270.23% | Details | |
| 10/13/2022 | BeiGene, Ltd. | BGNE | Upgrade | Outperform (Market Perform) |
125.51 (184.71) |
47.17% | Details | |
| 10/12/2022 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | Deciphera | DCPH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Blueprint Medicines | BPMC | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/27/2022 | Agios Pharma | AGIO | Upgrade | Outperform (Market Perform) |
19.51 (35.59) |
82.42% | Details | |
| 7/25/2022 | Regeneron Pharma | REGN | Downgrade | Market Perform (Outperform) |
586.11 (618.03) |
5.45% | Details | |
| 6/10/2022 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2022 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
657.15 (618.03) |
-5.95% | Details | |
| 5/23/2022 | Radius Health | RDUS | New Coverage | Market Perform (N/A) |
5.84 (30.00) |
413.7% | Details | |
| 5/23/2022 | Pfizer | PFE | New Coverage | Market Perform (N/A) |
50.65 (24.72) |
-51.19% | Details | |
| 5/23/2022 | Gilead Sciences | GILD | New Coverage | Market Perform (N/A) |
63.27 (86.72) |
37.06% | Details | |
| 5/23/2022 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
286.27 (746.37) |
160.72% | Details | |
| 5/23/2022 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
244.77 (347.01) |
41.77% | Details | |
| 5/23/2022 | Abbvie | ABBV | New Coverage | Underperform (N/A) |
151.72 (234.76) |
54.73% | Details | |
| 5/13/2022 | Cullinan Management | CGEM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2022 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2022 | BeiGene, Ltd. | BGNE | Downgrade | Market Perform (Outperform) |
183.33 (125.51) |
-31.54% | Details | |
| 2/23/2022 | Agios Pharma | AGIO | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/17/2022 | Blueprint Medicines | BPMC | Downgrade | Market Perform (Outperform) |
74.90 (129.46) |
72.84% | Details | |
| 12/20/2021 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
3.06 (2.06) |
-32.68% | Details | |
| 12/10/2021 | Zymeworks | ZYME | Upgrade | Outperform (Market Perform) |
16.12 (23.88) |
48.14% | Details | |
| 11/24/2021 | Aura Biosciences | AURA | New Coverage | Outperform (N/A) |
19.82 (7.02) |
-64.58% | Details | |
| 11/18/2021 | Agios Pharma | AGIO | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/12/2021 | Forma Therapeutics | FMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2021 | HOOKIPA Pharma Inc. | HOOK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2021 | Theseus Pharmaceuticals Inc. | THRX | New Coverage | Outperform (N/A) |
17.12 (4.06) |
-76.29% | Details | |
| 10/28/2021 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2021 | Mirati Therapeutics | MRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/20/2021 | Tango Therapeutics Inc. | TNGX | New Coverage | Outperform (N/A) |
17.30 (28.39) |
64.1% | Details | |
| 7/29/2021 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2021 | Elevation Oncology | ELEV | New Coverage | Outperform (N/A) |
12.10 (0.37) |
-96.94% | Details | |
| 6/17/2021 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2021 | Forma Therapeutics | FMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2021 | Forma Therapeutics | FMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | Epizyme | EPZM | Upgrade | Outperform (Underperform) |
6.81 (1.47) |
-78.41% | Details | |
| 4/14/2021 | Global Blood Therapeutics | GBT | New Coverage | Outperform (N/A) |
40.18 (68.49) |
70.46% | Details | |
| 3/16/2021 | Merus N.V. | MRUS | New Coverage | Outperform (N/A) |
22.04 (94.15) |
327.18% | Details | |
| 3/11/2021 | AVEO Pharmaceuticals | AVEO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2021 | Agios Pharma | AGIO | Downgrade | Market Perform (Outperform) |
47.44 (35.59) |
-24.98% | Details | |
| 2/26/2021 | Agios Pharma | AGIO | Downgrade | Market Perform (Outperform) |
50.29 (47.44) |
-5.67% | Details | |
| 2/25/2021 | Zymeworks | ZYME | Downgrade | Market Perform (Outperform) |
40.30 (23.88) |
-40.74% | Details | |
| 2/10/2021 | Deciphera | DCPH | Upgrade | Outperform (Market Perform) |
48.32 (25.59) |
-47.04% | Details | |
| 2/2/2021 | Cullinan Management | CGEM | New Coverage | Outperform (N/A) |
33.77 (17.75) |
-47.44% | Details | |
| 12/28/2020 | Kinnate Biopharma | KNTE | New Coverage | Outperform (N/A) |
38.00 (2.65) |
-93.03% | Details | |
| 12/22/2020 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2020 | Cogent | COGT | New Coverage | Outperform (N/A) |
10.53 (36.31) |
244.82% | Details | |
| 12/8/2020 | Forma Therapeutics | FMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2020 | HOOKIPA Pharma Inc. | HOOK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Epizyme | EPZM | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/22/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/14/2020 | Deciphera | DCPH | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/13/2020 | AVEO Pharmaceuticals | AVEO | New Coverage | Outperform (N/A) |
4.40 (15.00) |
240.91% | Details | |
| 8/7/2020 | Puma Biotechnology | PBYI | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/28/2020 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 7/14/2020 | Forma Therapeutics | FMTX | New Coverage | Outperform (N/A) |
38.53 (20.01) |
-48.07% | Details | |
| 6/1/2020 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/29/2020 | Deciphera | DCPH | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/29/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2020 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
31.76 (3.68) |
-88.41% | Details | |
| 4/27/2020 | Clovis Oncology | CLVS | Downgrade | Underperform (Market Perform) |
9.03 (0.08) |
-99.11% | Details | |
| 3/10/2020 | Deciphera | DCPH | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/4/2020 | BeiGene, Ltd. | BGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/27/2020 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/24/2020 | Epizyme | EPZM | Downgrade | Market Perform (Outperform) |
26.72 (1.47) |
-94.5% | Details | |
| 1/16/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2019 | Deciphera | DCPH | Upgrade | Market Perform (Underperform) |
39.07 (25.59) |
-34.5% | Details | |
| 9/30/2019 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2019 | Clovis Oncology | CLVS | Downgrade | Market Perform (Outperform) |
4.59 (0.08) |
-98.26% | Details | |
| 7/31/2019 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/31/2019 | Mirati Therapeutics | MRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2019 | HOOKIPA Pharma Inc. | HOOK | New Coverage | Outperform (N/A) |
13.84 (0.84) |
-93.93% | Details | |
| 2/15/2019 | Agios Pharma | AGIO | Upgrade | Outperform (Market Perform) |
54.03 (35.59) |
-34.13% | Details | |
| 1/8/2019 | Loxo Oncology | LOXO | Downgrade | Market Perform (Outperform) |
139.87 (234.80) |
67.87% | Details | |
| 1/7/2019 | Epizyme | EPZM | Upgrade | Outperform (Market Perform) |
5.98 (26.72) |
346.82% | Details | |
| 12/4/2018 | Clovis Oncology | CLVS | Upgrade | Outperform (Market Perform) |
19.08 (4.59) |
-75.94% | Details | |
| 12/4/2018 | Tesaro | TSRO | Downgrade | Market Perform (Outperform) |
46.38 (74.96) |
61.62% | Details | |
| 10/1/2018 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2018 | Incyte | INCY | New Coverage | Market Perform (N/A) |
66.59 (104.40) |
56.78% | Details | |
| 9/25/2018 | Clovis Oncology | CLVS | New Coverage | Market Perform (N/A) |
32.38 (19.08) |
-41.07% | Details | |
| 9/25/2018 | Agios Pharma | AGIO | New Coverage | Market Perform (N/A) |
73.56 (54.03) |
-26.55% | Details | |
| 9/25/2018 | Tesaro | TSRO | New Coverage | Outperform (N/A) |
37.69 (46.38) |
23.06% | Details | |
| 9/25/2018 | Seattle Genetics | SGEN | New Coverage | Outperform (N/A) |
77.76 (228.74) |
194.16% | Details | |
| 9/25/2018 | Loxo Oncology | LOXO | New Coverage | Outperform (N/A) |
159.27 (139.87) |
-12.18% | Details | |
| 9/25/2018 | Deciphera | DCPH | New Coverage | Underperform (N/A) |
38.97 (39.07) |
0.26% | Details | |
| 9/25/2018 | Blueprint Medicines | BPMC | New Coverage | Outperform (N/A) |
69.61 (129.46) |
85.98% | Details | |
| 9/25/2018 | BeiGene, Ltd. | BGNE | New Coverage | Outperform (N/A) |
163.97 (184.71) |
12.65% | Details |
